Premium
Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy
Author(s) -
Goldfarb Adina R.,
Weimer Louis H.,
Brannagan Thomas H.
Publication year - 2005
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20244
Subject(s) - rituximab , medicine , dysautonomia , gammopathy , immunology , monoclonal , monoclonal antibody , antibody , disease
Rituximab, a monoclonal antibody against B‐cell membrane marker CD‐20, is an effective treatment for immunoglobulin M (IgM) monoclonal anti–myelin‐associated glycoprotein (MAG) neuropathies. We report a patient with an autonomic and painful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, responsive to rituximab. Treatment resulted in a decline in total IgM and improvement in the patient's painful neuropathy and dysautonomia. Rituximab may be an effective and tolerable treatment for autonomic and sensory neuropathy associated with IgM monoclonal gammopathy. Muscle Nerve, 2005